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Abstract
It has been difficult to correlate the quality of CD8z T cell responses with protection against viral infections. To investigate
the relationship between efficacy and magnitude of T cell responses, we quantify the rate at which individual CD8z effector
and memory T cells kill target cells in the mouse spleen. Using mathematical modeling, we analyze recent data on the loss
of target cells pulsed with three different peptides from the mouse lymphocytic choriomeningitis virus (LCMV) in mouse
spleens with varying numbers of epitope-specific CD8z T cells. We find that the killing of targets follows the law of mass-
action, i.e., the death rate of individual target cells remains proportional to the frequency (or the total number) of specific
CD8z T cells in the spleen despite the fact that effector cell densities and effector to target ratios vary about a 1000-fold.
The killing rate of LCMV-specific CD8z T cells is largely independent of T cell specificity and differentiation stage. Our results
thus allow one to calculate the critical T cell concentration at which growth of a virus with a given replication rate can be
prevented from the start of infection by memory CD8z T cell response.
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Introduction
Vaccination is one of the most successful medical achievements
of the last century. Due to our limited understanding of the
correlates of protection, most vaccines have been developed by a
trial and error approach, and we have yet failed to deliver vaccines
for important diseases like AIDS or malaria. It is generally
believed that most of the currently used vaccines provide
protection by inducing high titers of pathogen-neutralizing
antibodies [1]. The efficacy of an antibody-inducing vaccine tends
to be proportional to the titer of neutralizing antibodies after
vaccination [2]. The new vaccines that are currently being
developed for devastating chronic infections, such as HIV and
malaria, are designed to stimulate cellular CD4z and CD8z T
cell responses. Such vaccines indeed elicit memory T cells, but at
present it remains unclear whether or not this T cell memory can
provide protection to infection, and which parameters of these T
cells would correlate with protection [1]. It has been suggested that
‘‘polyfunctional’’ memory CD4z T cells, which produce a variety
of different cytokines [3], are superior in providing protection to
infection with Leishmania [4], and that polyfunctional memory
CD8z T cells are protective against SIV infection [5]. Evidence
from HIV infected patients suggests that memory T cells loose
functionality when viral loads are high [6,7], arguing that the
frequency of polyfunctional memory T cells is a consequence of
the level of protection rather than its cause.
Our limited understanding of the level of protection provided by
memory T cells is partly due to the fact that the functionality of
effector and memory T cells is typically measured in vitro.T h e r ei s
very little quantitative data on the control of pathogen growth in
tissues by T cell immunity [8,9]. To quantify cytotoxic efficacy of
CD8z Tc e l l sin vivo one can transfer target cells that are pulsed with
viral peptides into mice harboring virus-specific effector or memory
CD8z T cells, and follow the subsequent elimination of the pulsed
target cells in the spleen [10–19]. We combine the data from recently
published experiments [16] with a recently developed mathematical
model [20–22] to quantify the rates at which individual effector or
memory CD8z T cells kill target cells pulsed with epitopes from the
mouse lymphocytic choriomeningitis virus (LCMV).
Even though the total number of LCMV-specific CD8z T cells
(and the ratio of killers to targets) in the spleen varies almost 3
orders of magnitude in these experiments, we found that the death
rate of peptide-pulsed targets due to CD8z T cell mediated killing
remains proportional to the frequency (or the total number) of
virus-specific CD8z T cells in the spleen. Thus the per capita killing
efficacy of CD8z T cells, i.e., the average rate at which an
individual CD8z T cell kills targets, is largely independent of the
density of the specific CD8z T cells. This suggests that vaccines
increasing the number of virus-specific CD8z T cells, should
proportionally increase the rate at which individual virus-infected
cells are cleared by that T cell response. Using information on the
rate of virus replication and the per cell killing efficacy of virus-
specific CD8z T cells one can calculate the critical number of
memory CD8z T cells required to control viral growth [23]. If
these results can be generalized to other lymphoid and
nonlymphoid organs and to other acute viral infections our results
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15959suggest that memory CD8z T cells are able to provide sterilizing
immunity, if they are to be present at the right place and at high
enough frequencies [24,25].
Materials and Methods
Cytotoxicity in vivo
We analyze published data on killing of peptide-pulsed
splenocytes by LCMV-specific effector and memory CD8z T
cells [16]. The experimental method of measuring cytotoxicity
of CD8z T cells in vivo has been described in detail elsewhere
[19], and the reader is referred to the original publications for
more detail. In the first set of experiments (‘‘in vivo LCMV
infection’’), target splenocytes were pulsed with NP396 or
GP276 peptides of LCMV (10 mM) or left unpulsed. Targets
were subsequently transferred into syngenic mice either infected
with LCMV 8 days previously (‘‘acutely infected’’ mice) or
recovered from LCMV infection (LCMV-immune or ‘‘memo-
ry’’ mice). At different times after the transfer of targets, spleens
were harvested, and the number of pulsed and unpulsed targets,
splenocytes, and peptide-specific CD8z T cells was calculated
(Fig. 1 A).
In the second set of experiments (‘‘adoptive transfer’’), 106 P14
CD8z T cells, expressing a TCR specific for the GP33 epitope of
LCMV, were adoptively transferred into recipient B6 mice which
were then infected i.p. with LCMV-Arm [26]. Eight (for effectors)
or 40 (for memory T cells) days later, different numbers of P14
CD8z T cells harvested from these mice were transferred into
new naive recipients (Fig. 1B). The number of effector CD8z T
cells transferred into different recipients was 106, 2|106, 107, and
2|107. The number of memory CD8z T cells transferred into
different recipients was 106, 2|106, and 107. Two hours later, two
populations of CFSE labeled splenocytes, one of which was pulsed
with the GP33 peptide of LCMV (1 mM), were transferred into
these recipient mice, harboring the transferred GP33-specific
effector or memory CD8z T cells. The percent of targets killed
was calculated at different times after target cell transfer (as
described earlier [16,19]). The ratio of the frequencies of peptide-
pulsed and unpulsed targets was used in fitting of the data and was
calculated as R~1{L=100, where L is the percent of peptide-
pulsed targets killed [19,22].
Mathematical model for the cytotoxicity in vivo assay
Details of the mathematical model proposed to describe
migration of injected targets from the blood to the spleen and
killing of peptide-pulsed targets in the spleen are given elsewhere
[20, 22, see also Supporting Information]. In short, target cells that
are injected i.v., migrate from the blood to the spleen at a rate s,
die at a rate E due to preparation techniques (independent of
CD8z T cell mediated killing), or migrate to other tissues and/or
die elsewhere at a rate d. In the spleen, targets die due to
preparation-induced death rate E, and peptide-pulsed targets also
die due to CD8z T cell mediated killing, described by the rate K.
The dynamics of the total number of unpulsed targets in the spleen
S(t) and the ratio of the frequency of peptide-pulsed to unpulsed
targets in the spleen R(t) was previously [22] shown to be
S(t)~
SB(0)s
d{E
1{e{(d{E)t   
e{Et, ð1Þ
R(t)~
(d{E)
(K{(d{E))
e{(d{E)t{e{Kt
1{e{(d{E)t
  
e{Et, ð2Þ
where d~szEzd is the rate of removal of cells from the blood
and SB(0)~5|106 is the initial number of unpulsed targets in the
blood [16].
We have shown previously that the rate of recruitment of target
cells from the blood to the spleen depends on the size of the spleen
[22]. Therefore, to describe recruitment of targets into the spleen
we let the rate of recruitment be s~a|Nsi where Nsi is the
number of splenocytes in the ith mouse and a is a coefficient [22].
It should be emphasized, however, that our conclusions are not
changed if we assume a fixed rate of recruitment of targets from
the blood to the spleen (results not shown). By estimating the death
Figure 1. Schematic representation of the in vivo cytotoxicity assays undertaken to investigate the quantitative details of CD8+ T
cell mediated killing of peptide-pulsed targets in the mouse spleen. In the first set of experiments (‘‘LCMV infection’’, panel A), B6 mice were
infected with LCMV-Arm and 8 or 37–100 days later, three populations of 5|106 target cells (pulsed with either NP296 or GP276 peptides of LCMV
and unpulsed) were transferred into these mice. In the second set of experiments (‘‘adoptive transfer’’, panel B), P14 TCR Tg CD8z T cells, specific to
the GP33 epitope of LCMV, were transferred into B6 mice and then infected with LCMV-Arm. Eight or 40 days later, different number of effector (day
8) or memory (day 40) P14 CD8z T cells from these mice were transferred into new naive B6 mice (in panel B, we shown an example where 2|106
effectors or memory CD8z T cells are transferred). Two hours later, two populations of 5|106 targets (pulsed with the GP33 peptide of LCMV and
unpulsed) were transferred into these mice now harboring GP33-specific CD8z T cells. In both sets of experiments, killing of peptide-pulsed targets
was measured in spleens of mice at different times after cell transfer [16].
doi:10.1371/journal.pone.0015959.g001
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unintended variation in the frequency (or number) of peptide-
specific CD8z T cells in individual mice [22]. This variation in
the frequency of epitope-specific CD8z T cells in spleens of
identically treated individual mice could be biologically relevant,
and hence influence the killing rate, or could represent
measurement noise. The absence of a positive correlation between
the number of targets killed and the CD8z T cell frequency in
identically treated mice suggests that the variation in this
frequency of epitope-specific CD8z T cells is due to measurement
noise (see Figs. S1 and S2 in Supporting Information S1).
To fit the data on recruitment of targets into the spleen and on
killing of peptide-pulsed targets in the spleen simultaneously, we
log-transform the data and the model predictions. To access lack
of fit of the data with repeated measurements we use the F-test
[27]. Fittings were done in Mathematica 5.2 using the routine
FindMinimum. Confidence intervals for parameters were calcu-
lated by bootstrapping the data with 1000 simulations [51].
Mathematical model for the virus dynamics
To describe the effect of the initial number of virus-specific
CD8z T cells on the virus dynamics, we formulate the following
mathematical model. In the absence of the CD8z T cell response
the virus population expands exponentially at the rate r from the
initial inoculum V0 and can potentially reach a maximum density
C (carrying capacity). CD8z T cell response starts with E0
precursors and follows a programmed response [28–30]. CD8z T
cells become activated at time Ton and the population expands at
the rate r. At time Toff the response stops. Virus-specific CD8z T
cell response clears the virus at the rate proportional to the product
of the density of the virus and CD8z T cell response. The
dynamics of the virus and virus-specific CD8z T cell response is
thus given by the following equations:
dV
dt
~rV 1{
V
C
  
{kVE, ð3Þ
E~
E0, if tv Ton,
E0er(t{Ton), if ToffwtwTon,
E0er(Toff{Ton), otherwise,
8
> <
> :
ð4Þ
where k is the killing efficacy of T cells, and E is the frequency (or
number) of virus-specific CD8z T cells. Because in the model the
virus is generally cleared before the peak of the CD8z T cell
response we do not model contraction and memory phases for the
virus-specific CD8z T cells.
Results
Death rate of targets following LCMV infection
To quantify the rates at which effector and memory CD8z T
cells kill their targets in a mouse spleen, we have previously
analyzed data from recently published experiments on the killing
of targets pulsed with either NP396 or GP276 peptides from
LCMV by peptide-specific effector or memory CD8z T cells
[16,22]. Mice, infected with LCMV-Armstrong develop a vigorous
CD8z T cell response that peaks 8 days after the infection [31,32].
By 15–30 days after the infection, most of effectors die and a
population of LCMV-specific memory CD8z T cells persists for
the life of the animal [32]. We have recently extended a
mathematical model to estimate the average death rate of target
cells in such a in vivo cytotoxicity assay [22]. The extended model
describes the recruitment of target cells from the blood to the
spleen, non-specific death of targets (e.g., due to the experimental
preparation), and killing of peptide-pulsed targets by peptide-
specific CD8z T cells in the spleen [22]. By fitting this model to
the data we previously estimated the average death rate of peptide-
pulsed targets due to killing by the effector or memory CD8z T
cell response (Table 1 in Supporting Information). Not surpris-
ingly, the death rate of targets was highly correlated with the
magnitude of the epitope-specific CD8z T cell response [22]. The
immunodominant NP396-specific effector CD8z T cell response
was most efficient at killing targets, while a smaller population, i.e.,
GP276-specific memory CD8z T cells, induced the slowest rate of
killing (see Fig. 3 and Table S1 in Supporting Information S1).
Death rate of targets following adoptive transfer
To further investigate the relationship between the death rate of
peptide-pulsed targets and the frequency (or the number) of
epitope-specific CD8z T cells in the spleen, we secondly analyzed
data from adoptive transfer experiments, involving the transfer of
different numbers of effector or memory CD8z T cells specific for
the GP33 epitope of LCMV [16]. Approximately 2 to 10% of the
adoptively transferred CD8z T cells accumulated in the mouse
spleen (Table 1). Transfer of different numbers of epitope-specific
CD8z T cells led to markedly different frequencies and numbers
of these cells in the spleen, and as a consequence, to markedly
different effector to target ratios (Table 1). Two hours after the
transfer of CD8z T cells, GP33-pulsed and unpulsed target cells
were transferred into the same mice, and killing of peptide-pulsed
targets was measured at different time points (Fig. 2).
Table 1. Estimates of parameters of the mathematical model
fitted to the data from the adoptive transfer experiments.
Parameter Mean 95% CIs E=T E,%
E, 106
cells
Cells
transferred
a,1 0 {11 min{1 cell{1 1.93 1.67–?
E,1 0 {3 min{1 1.35 0.28–1.97
d,1 0 {2 min{1 0.79 0.52–?
KE
1 ,1 0 {3 min{1 1.28 0.96–1.50 0.14 0.06 0.05 106
KM
1 ,1 0 {3 min{1 1.08 0.81–3.83 0.09 0.04 0.03
KE
2 ,1 0 {3 min{1 1.83 1.06–2.05 0.34 0.18 0.10 2|106
KM
2 ,1 0 {3 min{1 1.35 0.76–1.59 0.25 0.15 0.09
KE
3 ,1 0 {2 min{1 3.23 1.27–4.48 23.7 0.87 0.68 107
KM
3 ,1 0 {2 min{1 1.29 0.72–1.51 9.48 1.25 1.05
KE
4 ,1 0 {2 min{1 3.20 1.21–3.96 44.4 1.54 1.43 2|107
In different experiments, 106, 2|106, 107 or 2|107 effector or memory CD8z T
cells were transferred resulting in the shown average effector to target ratio
E=T , average percentage or the total number of transferred cells in spleens of
the recipient mice. We estimated the death rate of peptide-pulsed targets due
to killing by effector (KE
i ) or memory (KM
i ) CD8z T cells for different numbers
of CD8z T cells transferred. Since the first measurements in these experimental
data were taken 1 hour after transfer of target cells, we obtained unbound
confidence intervals for the parameters a and d that determine the rate of
recruitment of target cells from the blood to the spleen and elsewhere,
respectively. Interestingly, to properly describe these data we require the
preparation-induced cell death rate that we have previously postulated to exist
[22], although in these experiments this rate was smaller than that during acute
LCMV infection (see Table 2 in Supporting Information). Note that in these
experiments the effector to target ratio E=T changes over 100 fold (from 0.1 to
over 10).
doi:10.1371/journal.pone.0015959.t001
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to the killing by GP33-specific effector or memory CD8z T cells,
we fitted the same model (Eqs. 1–2) to these data (Table 1). The
model described the data very well with the exception of one time
point where very few unpulsed targets were recruited into the
spleen (Fig. 2A at 2|107 effector CD8z T cell transferred; lack of
fit test with this time point removed: F20,50~0:92, p~0:56). As
expected, there was a strong correlation between the number of
GP33-specific CD8z T cells that were transferred and the
estimated death rate of peptide-pulsed targets (Table 1 and Fig. 3).
Killing in vivo follows the law of mass-action
From these two types of experiments, we have in total 11
estimates for the average death rate of target cells elicited by
LCMV-specific CD8z T cells, present at frequencies that vary a
100-fold or numbers that vary almost a 1000-fold (Tables 1 and 2
in the Supporting Information). We find a strong positive
correlation between the average death rate of targets K and the
average frequency (Fig. 3A), or the average number (Fig. 3B), of
epitope-specific CD8z T cells in the mouse spleen. Importantly,
the slope of the log{log correlation was not significantly
different from one, suggesting that the death rate of peptide-
pulsed targets is simply proportional to the frequency, or the total
number, of epitope-specific CD8z T cells in the spleen, i.e.,
K~kE1. This linear dependence of the death rate of targets on
the specific CD8z T cells was confirmed by normalizing the death
rate of pulsed targets K by the frequency (or the number) of
epitope-specific CD8z T cells in the spleen (i.e., by plotting
k~K=E in Fig. 4). This constant level of the per capita killing
efficacy of CD8z T cells k was observed over a 102 fold changes
in the frequency and almost 103 fold change in the number of
epitope-specific CD8z T cells. These results suggest that killing of
target cells pulsed with LCMV peptides, by LCMV-specific CD8z
T cells conforms to the law of mass-action, whereby the death rate
of targets remains proportional to the frequency (or the number) of
epitope-specific CD8z T cells [23,33].
Predicting the number of memory CD8z T cells needed for
protection
Our result on mass-action killing allows for a simple estimate of
the level of virus-specific memory CD8z T cells that is required to
provide protection to a subsequent viral infection [23]. We
formulate a mathematical model that describes the dynamics of
the virus and virus-specific CD8z T cell response (see eqns. (3)–(4)
in Materials and Methods). When the initial number of virus-
specific CD8z T cells is low, the virus grows until reaches carrying
capacity and then is cleared by the expanded CD8z T cell
response (Fig. 5A). However, if the initial number of virus-specific
memory CD8z T cells is large enough, viral population declines
after the infection (Fig. 5B). In the model, to prevent viral growth
one requires that r{kEv0, implying that the level of memory
cells E should exceed r=k. For instance, for LCMV-Armstrong
with an initial replication rate of r~5 per day [34–36], and an
estimated killing rate of k~3:8|10{5 per cell per day (Fig. 4), we
would predict that E~r=k~1:3|105 memory CD8z T cells per
spleen should be able to provide sterilizing immunity against
Figure 2. Fits of the mathematical model to data involving adoptive transfer of different numbers of GP33-specific effector (panels
A&C) or memory (panels B&D) CD8+ T cells. Panels A and B show that the number of unpulsed targets in the spleen at different times after cell
transfer remains approximately constant. Panels C and D show the decrease in the ratio of the frequencies of peptide-pulsed and unpulsed targets in
the spleen over time. Different symbols denote data from different adoptive transfer experiments with 106, 2|106, 107,o r2|107 P14 cells
transferred. Filled symbols denote individual mouse measurements with the averages per time point being connected by solid lines. Open symbols
are the model predictions with averages being connected by dashed lines. Parameters providing the best fits of the model are shown in Table 1. Note
that in panel A, the model can not predict the decline in the number of unpulsed targets with time in experiments with transfer of 2|107 GP33-
specific effectors. Such decline in the number of unpulsed targets in the spleen is unexpected and is most likely due to a measurement error.
doi:10.1371/journal.pone.0015959.g002
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prediction is that one needs to know the number, and/or the
recruitment, of cytotoxic effector cells in the organ in which the
virus is initially replicating. For the case of LCMV-Armstrong
replicating mainly in the spleen after intraperitoneal infection, the
density of LCMV-specific memory T cells in the spleen should be
a strong predictor of the protection against the infection. It is
interesting to note that it was previously found that 3:5|105
LCMV-specific memory CD8z T cells are sufficient to clear
chronic LCMV clone 13 infection [37] which is close to our
estimate of 1:3|105 required to clear LCMV-Armstrong.
For viruses infecting other organs (e.g., flu infecting lung
epithelial cells) predicting the number of CD8z T cells required
for protection may be more difficult because one has to estimate
accumulation of effector/memory cells in that organ following
reinfection (e.g., lung). The efficacy of virus-specific CD8z T cells
at killing targets in peripheral organs could be different from that
in the spleen and this difference could further complicate the
prediction of the number of memory CD8z T cells required for
protection.
Our results confirm and extend recent findings on killing of
peptide-pulsed targets by effector CD8z T cells specific to
ovalbumin in collagen-fibrin gels in vitro [23]. The authors also
suggested that killing of targets in gels also follows the law of mass-
action with the death rate of targets increasing with CD8z T cell
concentration, although the range of T cell concentrations at which
this dependence was seen was much smaller (about 4–10 fold).
There are also quantitative differences: we find much faster killing
rates (k&4|10{9 ml cell{1min{1 in vivo assuming that spleen
volume is 0.15 ml [23], vs. 8|10{10 ml cell{1 min{1 found in
gels).This differencecould be dueto intrinsicdifferencesinkilling in
vitro and in vivo, dueto different ways of obtainingactivated CD8z
T cells, or due to artifacts in the in vivo cytotoxicity assay (see
Discussion). Our current results support the notion that for a given
viral infection there is a critical T cell concentration at which viral
growth can be suppressed (Fig. 5) providing support for the
development of sterilizing T cell-based vaccines [24,25].
Discussion
Recent interest in T cell based vaccines against several chronic
infections of humans requires the development of experimental
and theoretical tools to access the efficacy of such vaccines [38,39].
It is generally believed that memory CD8z T cells induced by
Figure 3. The estimated death rate of peptide-pulsed targets due to killing by epitope-specific CD8+ T cells is proportional to the
average percent (panel A) or average number (panel B) of epitope-specific CD8+ T cells in the spleen. Note that the percent of antigen-
specific CD8z T cells is calculated among all cells in the spleen. Estimates are given for targets pulsed with NP396 (.), GP276 (m), or GP33 (&)
peptides from LCMV. Filled symbols are for killing by effector CD8z T cells, and open symbols are for killing by memory CD8z T cells. Lines show the
linear regression for the log{log transformed estimates of the death rate and density of CD8z T cells. Slopes for the regressions are not statistically
different from one (panel A: slope=1.13, p~0:30; panel B: slope=0.98, p~0:80).
doi:10.1371/journal.pone.0015959.g003
Figure 4. The estimated per capita killing efficacy of CD8+ T cells is independent of the average percent (panel A) or average
number of epitope-specific CD8+ T cells in the spleen. We estimate the killing efficacy k by dividing the death rate of targets K by the
frequency (panel A) or the number (panel B) of epitope-specific CD8 T cells in the spleen E. Notations are the same as in Fig. 3. Lines show linear
regression for the estimates of the killing efficacy and log transformed frequency (panel A) or number (panel B) of epitope-specific CD8z T cells.
Slopes for the regressions are not statistically different from zero (panel A: slope=0.89, p~0:19; panel B: slope=20.06, p~0:91). A large positive
slope for the correlation between per capita killing k and the frequency of epitope-specific CD8z T cells in panel A is due to an outlier for killing by
NP396-specific effector CD8z T cells. Removing this outlier led to the estimated slope=0.06, p~0:90. The average killing efficacy of CD8z T cells is
2:33 min{1 (panel A) or 2:62|10{8 cell{1min{1 (panel B).
doi:10.1371/journal.pone.0015959.g004
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cells react only to infected cells, i.e., after the infection has been
established, and because CD8z effector T cells operate at
relatively high effector:target ratios [39]. However, a recent study
has shown that memory CD8z T cells can provide sterilizing
immunity against malaria in mice; although for protection a very
large population of memory cells was required [24]. Similarly,
protection to small doses of SIV was observed in monkeys only if
large and active populations of specific CD8z T cells were
maintained by a chronic infection continuously expressing SIV
epitopes [25].
Quantitative approaches aimed at estimating the in vivo efficacy
of effector and memory CD8z T cells, and the effects of CD8z T
cell densities on the control of pathogens, help to understand what
densities need to be induced by T cell-based vaccines, and whether
or not this is feasible. By fitting mathematical models to in vivo data
we found that the death rate of targets due to killing by LCMV-
specific CD8z T cells is simply proportional to the average
frequency (or number) of epitope-specific CD8z T cells in the
mouse spleen (Fig. 4). This is a surprising result because in these
experiments the frequencies of LCMV-specific CD8z T cells in
the spleen vary about a 100-fold (from 0.06% to 6%), their
numbers vary almost a 1000-fold, and the killer to target ratio
varies over 1000 fold. Technically this means that the killing of
targets by CD8z T cells follows the law of mass action [23,33,40],
and that CTLs do not compete for access to targets whenever their
frequencies in the spleen remain below 6% of the splenocytes (or
their numbers below *107 cells). From basic principles of cell
interactions one does expect that the death rate of targets should at
some point saturate when the density of killer CD8z T cells
increases [41–44]. In particular, it was found in in vitro experiments
that the death rate of targets in vitro bound by 2 CTL is not
dramatically different from death rate of targets bound by 3 or 4
CTLs [42]. Furthermore, in in vitro experiments involving the 51Cr
release assay, killing often saturates at reasonably small E/T ratios
(e.g., in [45] at E/T around 10). In our in vivo experiments, E/T
ratio varied from 0.1 (adoptive transfer experiments) to over 100
(endogenous response to LCMV). Therefore, it is surprising that in
vivo the death rate of targets remains simply proportional to the
density of killers. Possible explanations for the lack of a saturation
in the death rate with CD8z T cell density in these in vivo data
vary from experimental artifacts to biological reality.
First, the observed high densities of epitope-specific CD8z T
cells in the spleen could still be too low to cause saturation in the
death rate of targets. At the peak of the immune response to
LCMV, NP396-specific CD8z T cells are the most abundant T
cell population in the spleen, and yet this population constitutes
only 6% of all splenocytes, which remains a fairly small fraction. If
saturation only occurs at even higher densities, our results would
be generic and killing would follow mass-action kinetics for
realistic effector cell densities.
Second, the mass-action could be an artifact of the experimental
procedure because the loss rate of target cells was only measured
after making a single cell suspension from the spleen, and sorting
the cells by their CFSE fluorescence. This experimental proce-
dure, and the time delay between the in vivo encounter between the
target cell and its specific killer cell, may give the targets ample
time to die after a brief, and perhaps marginal exposure, to a
specific CD8z T cell. Thus, it seems possible that in this in vivo
cytotoxicity assay largely measures the initial rate of encounter
between target cells and CD8z T cells, and hardly the rate of
killing of targets. Such initial encounter rates would a priori be
expected to follow mass-action kinetics. Our estimated half-life of
NP396 pulsed target cells is about three minutes [22], which is
much shorter than the 10 to 60 minutes it takes a target cell to die
after a contact with the CTL in vitro or in vivo [42,46,47]. At high
effector to target ratios the three minutes time might be sufficient
to have an encounter between most of targets and an effector cell,
and possibly to have some perforin molecules being delivered to
the target cell. Such an encounter need not lead to to immediate
death of the target cells in vivo, but their subsequent experimental
manipulation in vitro could lead to cell death at the time the cell
suspensions are produced. If this is true, we are overestimating the
death rate, and if prolonged contacts between effectors and targets
are required for cell death in vivo, we may be underestimating the
saturation effects.
The possibility that preparation of cell suspensions could lead to
an early death of peptide-pulsed targets is corroborated by recent
work demonstrating that granzymes A and B are dispensable for
the killing of peptide-pulsed targets by CD8z T cells or NK cells
in vivo, despite its importance in the control of viral infections
[48]. In the experiments, an initial delivery of perforin might
suffice to induce cell death during the experimental preparation of
the cells.
Finally, it is possible that our results arise due to the fact that we
combine data on the killing by CD8z T cells of different
specificities. It has been proposed that the per capita killing efficacy
of NP396-specific CD8z T cells is higher than that of GP276-
specific CD8z T cells [20,21]. However, since the per capita killing
efficacy of CD8z T cells of different specificities varies only 2–5
Figure 5. Predicted changes in viral load for different initial numbers of virus-specific memory CD8+ T cells. Using the model given in
eqns. (3)–(4), we plot the dynamics of the virus (V) over the course of infection when the initial number of virus-specific memory CD8z T cells (E)i s
low (E0~103, panel A) or high (E0~104,105,2 |105, panel B). Viral density declines following infection as memory CD8z T cells reach the threshold
level of 1:3|105 cells per spleen. Other parameters are r~5day{1, C~107, k~3:8|10{5 day{1, T on~2days, r~1:9 day{1, T off ~7 days [29].
doi:10.1371/journal.pone.0015959.g005
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more than two orders of magnitude, this seems an unlikely
explanation.
A recent study re-analyzing the same published data suggested
that killing of targets saturates when the frequency of LCMV-
specific CD8z T cells breaches 0:2{1:3% in the spleen [44]. This
is in disagreement with the range of frequencies that we find
consistent with mass-action killing. The contradiction may be due
to the different ranges in frequencies used to analyze the data. In
the previous study, the variation in frequencies of epitope-specific
CD8z T cells in individual mice was considered to be correlated
with killing of targets in these mice. This variation in frequency of
a given epitope-specific response was in general relatively small,
however. At such small scales evidence for saturation can come
about from noise in the measurements of CD8z T cell frequencies
in spleens of individual mice (Ganusov and De Boer, ms. in
preparation). In our current analysis we focused on a large
variation in CD8z T cell frequencies/numbers between different
epitopes (100 to 1000 fold) and therefore we believe that our
results are more reliable.
It remains unclear whether the killing of targets depends on the
frequency or on the total number of epitope-specific CD8z T cells
in the spleen [22]. We find mass-action kinetics for both cases
(Fig. 4). To estimate whether individual effector CD8z T cells are
more efficient killers than individual memory CD8z T cells, one
needs to know whether killing depends on cell frequencies or on
cell numbers. Memory NP396- and GP276-specific CD8z T cells
are only half as efficient killers as effectors of the same specificity
when killing is considered to be proportional to cellular
frequencies (Fig. 4A and [21]). In contrast, if killing depends on
cell numbers, individual NP396- and GP276-specific memory T
cells are more efficient killers than the corresponding effector cells
(Fig. 4B). Understanding whether killing frequency- or number-
dependent is critical for prediction of the efficacy of T-cell based
vaccines, in part, because the number and the frequency of
memory T cells are affected differently following infections with
heterologous viruses [49,50]. If killing indeed generally obeys
mass-action kinetics one should be able to generalize the
calculations of the critical T cell concentration to other viruses
[23], and this theoretical framework could therefore provide
guidelines for estimating the efficacy of T-cell based vaccines.
Supporting Information
Supporting Information S1 Here we show a mathematical
model for the in vivo cytotoxicity assay, estimates of the death rate
of targets pulsed with NP396 and GP276 peptides following acute
LCMV infection and the correlations between the fraction of
target cells killed and the frequency of epitope-specific CD8z T
cells in the spleen.
(PDF)
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